Mundipharma EDO

Mundipharma EDO GmbH: US FDA Grants Orphan Drug Designation for Tinostamustine in Very Rare Blood Cancer

FOR EX-US MEDICAL AND TRADE MEDIA ONLY - T-cell prolymphocytic leukaemia is an extremely rare and aggressive T-cell leukaemia, with very limited effective treatment options1,2 - Tinostamustine is in very early phase clinical trials to investigate it as a potential future treatment option in this area of significant ...